Contents Menu

Fujii Yasuhiko

Affiliate Master Yamaguchi University

Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma

The bulletin of the Yamaguchi Medical School Volume 36 Issue 1-2 Page 21-27
published_at 1989-06
A020036000104.pdf
[fulltext] 583 KB
Title
Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma
Creators Tanaka Masahisa
Creators Azuno Yoichi
Creators Yoshizaki Yoshiki
Creators Hatao Katsuhiro
Creators Fujii Yasuhiko
Creators Okubo Masashi
Creators Inoue Yasushi
Creators Matsutani Akira
Creators Yaga Ken
Creators Fujii Shinya
Creators Ishida Yoji
Creators Kaku Kohei
Creators Matsumura Shigeichi
Creators Kaneko Toshio
Creators Shinohara Kenji
Creators Hiroshige Yukio
Creators Matsumoto Noboru
Source Identifiers
Creator Keywords
Non-Hodgkin's Lymphoma Chemotherapy CHOP-Pepleo COP-Pepleo
Combination chemotherapy with CHOP-Pepleo regimen (cyclophosphamide, adriamycin, vincristine, prednisolone, and pepleomycin), or COP-Pepleo refimen (cyclophosphamide, vincristine, prednisolone, and pepleomycin), was used as a remission induction therapy for patients with mostly advanced non-Hodgkin's lymphomas. Among 23 patients treated with CHOP-Pepleo or CHOP without Pepleo (5 patients), 57% achieved complete remission with 78% overall response (complete remission plus partisl remission). Among 12 patients treated with COP-Pepleo, 50% achieved complete remissions with 83% overall response. No significant difference was odserved in response rates between two groups. Median follow-up durations ware 14 months for CHOP-People and 16 months for COP-Pepleo and 4 patients (67%) treated with COP-Pepleo relapsed within 20 months after achieving complete remission. Relapse-free survival rates at 4 years ware 54% for CHOP-Pepleo and 34% for COP-Pepleo. Each survival curve in the patients treated with CHOP-Pepleo or COP-Pepleo showed a plateau after 24 months. Though the addition of adriamycin did not improve complete remission rate significantly as a whole, the complete remission rate in stage Ⅳ , overall survival and relapse-free survival ware favorably inproved by the addition of adriamycin. Further study will be needed to assess the effect of adriamycin on response and survival in patients eith non-Hodgkin's lymphomas.
Subjects
医学 ( Other)
Languages eng
Resource Type departmental bulletin paper
Publishers Yamaguchi University Graduate School of Medicine
Date Issued 1989-06
File Version Version of Record
Access Rights open access
Relations
[ISSN]0513-1812
[NCID]AA00594272
Schools 医学部